Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line

Human Gene Therapy

Volumn 11, Issue 5, 2000, Pages 739-750

  Osanto, S ^a,b   Schiphorst, P P ^a   Weijl, N I ^a   Dijkstra, N ^a   Van Wees, A ^a   Brouwenstein, N ^a   Vaessen, N ^a   Van Krieken, J H J M ^a   Hermans, J ^b   Cleton, F J ^a   Schrier, P I ^a  

^a Department of Clinical Oncology ^*  (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; MELANOMA VACCINE; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; FEMALE; HUMAN; LYMPHADENITIS; MALE; MELANOMA; METASTASIS; TUMOR REGRESSION; VACCINATION; VITILIGO;

ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; FEMALE; HLA-A1 ANTIGEN; HLA-A2 ANTIGEN; HLA-B8 ANTIGEN; HLA-C ANTIGENS; HUMANS; IMMUNOTHERAPY; INFLAMMATION; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0034689496     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050015635     Document Type: Article

References (32)

1. Aarnoudse, C.A., Van Den Doel, P.B., Heemskerk, B., and Schrier, P.I. (1999). Interleukin-2 induced melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int. J. Cancer 82, 442-448.
2. Abdel-Wahab, Z., Dar, M., Osanto, S., Fong, T., Vervaert, C.E., Hester, D., Jolly, D., and Seigler, H.F. (1997). Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon. Cancer Gene Ther. 4, 33-41.
3. Altman, J.D., Moss, P.A.H., Goulder, P.J.R., Barouch, D.H., McHeyzer-Williams, M.G., Bell, J.I., McMichael, A.J., and Davis, M.M. (1996). Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94-96.
4. Arienti, F., Sulé-Suso, J., Belli, F., Mascheroni L., Rivoltini, L., Melani, C., Maio, M., Cascinelli, N., Colombo, M.P., and Parminai, G. (1996). Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum. Gene Ther. 7, 1955-1963.
5. Armstrong, T.D., Clements, V.K., Martin, B.K., and Ting, J. P.-Y. (1997). Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc. Natl. Acad. Sci. U.S.A. 94, 6886-6891.
6. Auffray, C., and Rougeon, F. (1980). Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA. Eur. J. Biochem. 107, 303-314.
7. Belli, F., Arienti, F., Sulé-Suso, J., Clemente, C., Mascheroni, L., Cattelan, A., Sanantonio, C., Gallino, G.F., Melani, C., Rao, S., Colombo, M.P., Maio, M., Cascinelli, N., and Parmiani, G. (1997). Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability. Cancer Immunol. Immunother. 44, 197-203.
8. Blankenstein, T., Qin, Z.H., Uberla, K., Muller, W., Rosen, H., Volk, H.D., and Diamantstein, T. (1991). Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J. Exp. Med. 173, 1047-1052.
9. Borysiewicz, L.K., Graham, S., Hickling, J.K., Mason, P.D., and Sissons, J.G. (1988). Human cytomegalovirus-specific cytotoxic T cells: Their precursor frequency and stage specificity. Eur. J. Immunol. 18, 269-275.
10. Brach, M.A., Hass, R., Sherman, M.L., Gunji, H., Weichselbaum, R., and Kufe, D. (1991). Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J. Clin. Invest. 88, 691-695.
11. Coulie, P.G. (1997). Human tumour antigens recognized by T cells: New perspectives for anti-cancer vaccines? Mol. Med. Today 3, 261-268. [Review]
12. Fearon, E.R., Itaya, T., Hunt, B., Vogelstein, B., and Frost, P. (1988). Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res. 48, 2975-2980.
13. Fearon, E.R., Pardoll, D.M., Itaya, T., Golumbek, P., Levitsky, H.I., Simons, J.W., Karasuyama, H., Vogelstein, B., and Frost, P. (1990). Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397-403.
14. Gansbacher, B., Zier, K., Daniels, B., Cronin, K., Bannerji, R., and Gilboa, E. (1990). Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1224.
15. Gelber, C., Plaksin, D., Vadai, E., Feldman, M., and Eisenbach, L. (1989). Abolishment of metastasis formation by murine tumor cells transfected with "foreign" H-2K genes. Cancer Res. 49, 2366-2373.
16. Golumbek, P.T., Lazenby, A.J., Levitsky, H.I., Jaffee, L.M., Karasuyama, H., Baker, M., and Pardoll, D.M. (1991). Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713-716.
17. Gribaudo, G., Ravaglia, S., Guandalini, L., Cavallo, R., Gariglio, M., and Landolfo, S. (1996). The murine cytomegalovirus immediate-early 1 protein stimulates NF-kappa B activity by transactivating the NF-kappa B p105/p50 promoter. Virus Res. 45, 15-27.
18. Hui, K.M., Sim, T., Foo, T.T., and Oei, A.A. (1989). Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene. J. Immunol. 143, 3835-3843.
19. Nabel, G.J., Nabel, E.G., Yang, Z.Y., Fox, B.A., Plautz, G.E., Gao, X., Huang, L., Shu, S., Gordon, D., and Chang, A.E. (1993). Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sci. U.S.A. 90, 11307-11311.
20. Nabel, G.J., Gordon, D., Bishop, D.K., Nickoloff, B.J., Yang, Z.Y., Aruga, A., Cameron, M.J., Nabel, E.G., and Chang, A.E. (1996). Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc. Natl. Acad. Sci. U.S.A. 93, 15388-15393.
21. Osanto, S., Brouwenstyn, N., Vaessen, N., Figdor, C.G., Melief, C.J., and Schrier, P.I. (1993). Immunization with interleukin-2 transfected melanoma cells. A phase I-II study in patients with metastatic melanoma. Hum. Gene Ther. 4, 323-330.
22. Palmer, K., Moor, J., Everard, M., Harris, J.D., Rodgers, S., Rees, R.C., Murray, A.K., Mascari, R., Kirkwood, J., Riches, P.G., Fisher, C., Thomas, J.M., Harries, M., Johnston, S.R.D., Collins, M.K.L., and Gore, M.E. (1999). Gene therapy with autologous, interleukin-2-secreting tumor cells in patients with malignant melanoma. Hum. Gene Ther. 10, 1261-1268.
23. Reed, J.C. (1997) Double identity for proteins of the Bcl-2 family. Nature (London) 387, 773-776.
24. Rosenberg, S.A., and White, D.E. (1996). Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy. J. Immunther. 19, 81-84.
25. Schiphorst, P.P., Van Wees, A., Dijkstra, N., Droogsma, A., Claas, F.H.J., Schrier, P.I., and Osanto, S. Limiting dilution analysis to determine tumor-specific CTL frequencies in melanoma patients vaccinated with HLA-class I matched allogeneic melanoma cells. Sumitted.
26. Schreiber, S., Kampgen, E., Wagner, E., Prikhammer, D., Trcka, J., Korschan, H., Lindemann, A., Dorffner, R., Kittler, H., Kasteliz, F., Kupcu, Z., Sinsky, A., Zatloukal, K., Buschle, M., Schmidt, W., Birnstiel, M., Kempe, R.E., Voight, T., Weber, H.A., Pehamberger, H., Mertelsmann, R., Bröcker, E.B., Wolff, K., and Stingl, G. (1999). Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a phase I study. Hum. Gene Ther. 10, 983-993.
27. Sensi, M., Farina, C., Maccalli, C., Lupetti, R., Nicolini, G., Anichini, A., Parmiani, G., and Berd, D. (1997). Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. J. Clin. Invest. 99, 710-717.
28. Soiffer, R., Lynch, T., Mihm, M., Jung, K., Rhuda, C., Schmollinger, J.C., Hodi, F.S., Liebster, L., Lam, P., Mentzer, S., Singer, S., Tanabe, K.K., Cosimi, A.B., Duda, R., Sober, A., Bhan, A., Daley, J., Neuberg, D., Parry, G., Rokovich, J., Richards, L., Drayer, J., Berns, A., Clift, S., Cohen, L.K., Mulligan, R.C., and Dranoff, G. (1998). Vaccination with irradiated autologous melanoma cells engineered to secete human ganulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U.S.A. 95, 13141-13146.
29. Strijbosch, L.W.G., Buurman, W.A., Does, R.J.M.M., Zinken, P.H., and Groenewegen, G. (1987). Limiting dilution assays. Experimental design and statistical analysis. J. Immunol. Methods 97, 133-140.
30. Tepper, R.I., Pattengale, P.K., and Leder, P. (1989). Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57, 503-512.
31. Thor Straten, P., Becker, J.C., Seremet, T., Brocker, E.B., and Zeuthen, J. (1996). Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma. J. Clin. Invest. 98, 279-284.
32. Van Elsas, A., Aarnoudse, C., Van der Minne, C.E., Van der Spek, C.W., Brouwenstijn, N., Osanto, S., and Schrier, P.I. (1997). Transfection of IL-2 augments CTL response to human melanoma cells in vitro: Immunological characterization of a melanoma vaccine. J. Immunother. 20, 343-353.